Vise Technologies Inc. Purchases 15,063 Shares of Relx Plc $RELX

Vise Technologies Inc. raised its position in shares of Relx Plc (NYSE:RELX) by 25.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,333 shares of the technology company’s stock after buying an additional 15,063 shares during the quarter. Vise Technologies Inc.’s holdings in Relx were worth $2,500,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Lazard Asset Management LLC raised its position in Relx by 12.1% during the first quarter. Lazard Asset Management LLC now owns 3,040,217 shares of the technology company’s stock valued at $100,783,000 after purchasing an additional 328,282 shares during the period. Bank of America Corp DE raised its stake in shares of Relx by 14.3% in the first quarter. Bank of America Corp DE now owns 4,180,034 shares of the technology company’s stock valued at $138,568,000 after acquiring an additional 522,619 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Relx by 697.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 159,681 shares of the technology company’s stock valued at $5,306,000 after acquiring an additional 139,663 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of Relx by 185.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 4,252,044 shares of the technology company’s stock worth $140,955,000 after purchasing an additional 2,763,766 shares during the period. Finally, Evelyn Partners Asset Management Ltd raised its position in Relx by 53.6% in the 1st quarter. Evelyn Partners Asset Management Ltd now owns 157,612 shares of the technology company’s stock worth $5,225,000 after purchasing an additional 55,028 shares during the period. 15.02% of the stock is currently owned by institutional investors.

Relx Stock Performance

Shares of Relx stock opened at $41.44 on Friday. Relx Plc has a twelve month low of $27.57 and a twelve month high of $43.49. The company has a debt-to-equity ratio of 5.23, a quick ratio of 0.40 and a current ratio of 0.45. The business has a 50-day moving average price of $36.27 and a 200 day moving average price of $34.52.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Weiss Ratings upgraded Relx from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 7th. Citigroup cut shares of Relx from a “buy” rating to a “neutral” rating in a report on Tuesday, October 20th. TD Cowen started coverage on Relx in a research report on Thursday, September 10th. They set a “buy” rating on the stock. TD Securities raised shares of Relx to a “strong-buy” rating in a research report on Friday, September 11th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Relx in a research note on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Relx presently has a consensus rating of “Moderate Buy”.

Relx Profile

RELX PLC is a global information-based analytics and decision tools company serving professional and business customers. The company provides data, software, research, and workflow solutions that help organizations make decisions, manage risk, improve productivity, and access specialized knowledge.

Its main business areas include scientific, technical, and medical information; risk and business analytics; legal information and technology; and industry-focused events. Products and services include research platforms such as ScienceDirect and Scopus, legal research and workflow solutions offered through LexisNexis, and risk-management, fraud-prevention, and identity solutions provided through LexisNexis Risk Solutions.

RELX serves customers internationally, including universities, researchers, law firms, government agencies, insurers, financial institutions, corporations, and healthcare professionals.